Today, Avanir Pharmaceuticals announced the details of its new patient assistance program for NUEDEXTA (dextromethorphan HBr and quinidine sulfate). This program is intended to assist patients who have been diagnosed with pseudobulbar affect (PBA) and meet established program criteria, to give them free access to NUEDEXTA.
Pseudobulbar affect patients have sudden, involuntary outbursts of crying or laughing without a stimulus to trigger those emotions. PBA can occur when certain neurologic diseases or injuries cause damage to the areas of the brain that control normal expression of emotion, resulting in disruption of brain signaling. NUEDEXTA is the first and only medication indicated for PBA that has been approved by the FDA. Avanir desires to ensure that cost constraints will not become a deterrent for any person who may benefit from this medication, regardless of income level or healthcare coverage. The company’s new patient assistance program has been created to that end as part of Avanir’s comprehensive patient support services.
Avanir’s patient support program, launched in May, complements two other financial assistance programs that are currently available for patients insured by commercial health plans or Medicare Part D. The addition of the patient assistance program for those who don’t have prescription drug coverage will now make NUEDEXTA available to most individuals who need it.
The patient assistance program gives eligible patients a six-month supply of NUEDEXTA at no cost to the patient. Participants in the program may qualify for ongoing assistance that is subject to periodic eligibility verification. For more information about NUEDEXTA patient services, call (855) 468-3339 or visit www.nuedexta.com.
Avanir Pharmaceuticals is a biopharmaceutical company engaged in providing innovative medicines to patients with central nervous system disorders of high unmet medical need. The company has extensively invested in its pipeline, and Avanir is dedicated to advancing medicines that can significantly improve the lives of patients and their loved ones. For more information, visit the company’s Web site at www.avanir.com.
Let us hear your thoughts below:
